anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention provides a pH response liposome for enhancing ultrasonic imaging and sensitization HIFU, and a preparation method and application thereof. The pH responsive liposome takes liposome as a carrier to load NH  4  HCO  3  And anticancer drugs. The pH response liposome provided by the invention can effectively gather and neutralize tumor acidity at tumor sites, thereby promoting reversion of tumor chemotherapy drug resistance and enhancement of PTX-induced ICD. The released carbon dioxide can not only enhance ultrasonic imaging, but also can be used as cavitation microbubbles to enhance HIFU. In addition, the treatment of Balb/c mouse U14 tumor by intravenous injection of PTN@lip NPs can be enhancedTherapeutic effects of Balb/c nude mice KLE tumor. Therefore, the novel HIFU thermosensitive and chemotherapy combined treatment strategy is expected to improve the existing clinical treatment dilemma and theoretically provides a new treatment direction of gynecological tumors.
FIELD: medicine. SUBSTANCE: present invention describes method of preparing taxane derivatives of formula (I) by esterifying protected baccatine III or 10-deacety- bacctine III using acid of formula (VII), removing protecting groups and subsequently acylating functional amino groups of side unit. Compounds of formula (I) have antitumor and antileukemic properties. In formula (I) and formula (VII) Ar is phenyl; R is hydrogen or acetyl; R 1  is benzoyl or R 2 -O-CO- in which R 2  is straight or branched C 1 -C 8 -alkyl; R 3  is trihalomethyl; R 4  is hydrogen atom or is identical with R 1  substitute. EFFECT: improved properties of taxane derivatives. 26 cl
Radiotherapy plays an irreplaceable role in lung cancer. However, due to the long duration of conventional fractionation irradiation, tumor cells will accelerate repopulation after 3 to 4 weeks during radiotherapy, resulting in decreased efficacy. Hypofractionated radiation is increasingly used in radiotherapy of lung cancer. It can shorten the overall treatment time, and can potentially reduce the effect of tumor accelerated repopulation. Compared with conventional radiotherapy, hypofractionated radiotherapy can theoretically obtain a higher biological effective dose (BED). The application of Stereotactic Body Radiation Therapy (SBRT) or Stereotactic Ablative Radiotherapy (SABR) in advanced or central lung cancer is restricted when the tumors are adjacent to important organs. Moderate hypofractionated radiotherapy can not only shorten the overall total treatment time, but also reduce the severe toxicities. It is widely used in lung cancer nowadays. However, most data of the tolerated doses for normal tissue and organs comes from conventional radiotherapy. Whether or not it is suitable for hypofractionated radiotherapy has not been determined. In our study, the incidences of Grade III and above radiation-reduced esophagitis and radiation-reduced pneumonia, as well as their predictors, were obtained by retrospective analysis of patients received moderate hypofractionated radiotherapy of 3Gy/f. At the same time, the efficacies of this scheme are also evaluated.
Participants randomized to the exercise group will receive 26 weeks of home-based, combined endurance and resistance training program under guidance and virtual supervision from exercise trainers. Exercise will be performed 5 days per week, with 3 days of endurance training using treadmill and 2 days of resistance training.
In a 4- to 6-year comparative trial (ADOPT) of glycemic control with monotherapy in drug-naïve patients recently diagnosed with type 2 diabetes mellitus, an increased incidence of bone fracture was noted in female patients taking rosiglitazone. Over the 4- to 6-year period, the incidence of bone fracture in females was 9.3% (60/645) for rosiglitazone versus 3.5% (21/605) for glyburide and 5.1% (30/590) for metformin. This increased incidence was noted after the first year of treatment and persisted during the course of the trial. The majority of the fractures in the women who received rosiglitazone occurred in the upper arm, hand, and foot. These sites of fracture are different from those usually associated with postmenopausal osteoporosis (e.g., hip or spine). Other trials suggest that this risk may also apply to men, although the risk of fracture among women appears higher than that among men. The risk of fracture should be considered in the care of patients treated with rosiglitazone, and attention given to assessing and maintaining bone health according to current standards of care.
BACKGROUND: Prostate cancer (PCa) is among the three main types of cancer. Although prostate-specific antigen (PSA) is routinely tested, it has disadvantages, such as poor prognostic ability. Therefore, finding more PCa markers and therapeutic targets remains a subject of study. CircRNAs have been found to have regulatory roles in various diseases, such as diabetes, Central Nervous System (CNS) neuropathy, etc. where their application in cancer is even more valuable. Therefore, this paper aims to search for differentially expressed circRNAs in PCa and find downstream targeting pathways related to autophagy.
METHOD: By detecting the expression of circRNA in the samples, hsa_circ_0119816 was finally identified as the research target. The properties of circRNA were verified by RNase R, actinomycin D, and fluorescence in situ hybridization (FISH). The downstream target miRNAs and target proteins were predicted by an online database, and the targeting relationship was verified using dual luciferase and RNA Immunoprecipitation. The effects of circRNAs and their downstream signalling pathways on prostate cancer cell proliferation, migration, EMT and autophagy were examined by CCK-8, Transwell, immunofluorescence and Western blotting.
RESULTS: CircBIRC6 is highly expressed in prostate cancer samples. Knockdown of its expression inhibits cell proliferation, invasion, EMT and autophagy and promotes apoptosis. CircBIRC6/miRNA-574-5p/DNAJB1 is a molecular axis that regulates prostate cancer cells.
The following table shows the amount of solvent required for solution of various concentrations:

When the required volume of solvent is greater than the capacity of the vial, the penicillin can be dissolved by first injecting only a portion of the solvent into the vial, then withdrawing the resultant solution and combining it with the remainder of the solvent in a larger sterile container.

Penicillin G potassium for injection is highly water soluble. It may be dissolved in small amounts of Water for Injection, or Sterile Isotonic Sodium Chloride Solution for Parenteral Use. All solutions should be stored in a refrigerator. When refrigerated, penicillin solutions may be stored for seven days without significant loss of potency.

Buffered penicillin G potassium for injection may be given intramuscularly or by continuous intravenous drip for dosages of 500,000, 1,000,000 or 5,000,000 units. It is also suitable for intrapleural, intraarticular, and other local installations.

THE 20,000,000 UNIT (20 MILLION UNIT) DOSAGE MAY BE ADMINISTERED BY INTRAVENOUS INFUSION ONLY.

(1) Intramuscular Injection: Keep total volume of injection small. The intramuscular route is the preferred route of administration. Solutions containing up to 100,000 units of penicillin per mL of diluent may be used with a minimum of discomfort. Greater concentration of penicillin G per mL is physically possible and may be employed where therapy demands. When large doses are required, it may be advisable to administer aqueous solutions of penicillin by means of continuous intravenous drip.

(2) Continuous Intravenous Drip: Determine the volume of fluid and rate of its administration required by the patient in a 24-hour period in the usual manner for fluid therapy, and add the appropriate daily dosage of penicillin to this fluid. For example, if an adult patient requires 2 liters of fluid in 24 hours and a daily dosage of 10 million units of penicillin, add 5 million units of 1 liter and adjust the rate of flow so the liter will be infused in 12 hours.

(3) Intrapleural or Other Local Infusion: If fluid is aspirated, give infusion in a volume equal to 1/4 or 1/2 the amount of fluid aspirated, otherwise, prepare as for an intramuscular injection.

(4) Intrathecal Use: The intrathecal use of penicillin in meningitis must be highly individualized. It should be employed only with full consideration of the possible irritating effects of penicillin when used by this route. The preferred route of therapy in bacterial meningitides is intravenous, supplemented by intramuscular injection.
The invention discloses a double-drug linked assembly unit and a double-drug targeting connector-drug conjugate. Specifically provided is a double-drug linked assembly unit shown in a formula VI, or a stereoisomer thereof, or an optical isomer thereof. The double-drug linked assembly unit can be connected with a targeting linker to obtain the double-drug targeting linker-drug conjugate molecule shown in the formula I. The double-drug targeting linker-drug conjugate can target tumor cells, reduce toxic and side effects on normal cells, and effectively overcome drug resistance of drugs. With ADCs already on the market: compared with DS-8201a, the ADC provided by the invention has obviously improved inhibition effect on breast adenocarcinoma cells and gastric carcinoma cells. The double-drug linked assembly unit and the double-drug targeting connector-drug conjugate have wide application prospects in preparation of antitumor drugs for prevention and/or treatment.
Participants in the Do-It-Yourself (DIY) control group will receive psychoeducation materials in W0. They will view content as usual (no DIY) and will receive surveys from W1 to W4 and follow-up surveys in W5 and at the end of W8.
AIM: Offspring of obese mothers are at high risk of developing metabolic syndrome and cognitive disabilities. Impaired metabolism has also been reported in the offspring of obese fathers. However, whether brain function can also be affected by paternal obesity has barely been examined. This study aimed to characterize the learning deficits resulting from paternal obesity versus those induced by maternal obesity and to identify the underlying mechanisms.
METHODS: Founder control and obese female and male Wistar rats were mated to constitute three first-generation (F1) experimental groups: control mother/control father, obese mother/control father, and obese father/control mother. All F1 animals were weaned onto standard chow and underwent a learning test at 4 months of age, after which several markers of glutamate-mediated synaptic plasticity together with the expression of miRNAs targeting glutamate receptors and the concentration of kynurenic and quinolinic acids were quantified in the hippocampus and frontal cortex.
RESULTS: Maternal obesity induced a severe learning deficit by impairing memory encoding and memory consolidation. The offspring of obese fathers also showed reduced memory encoding but not impaired long-term memory formation. Memory deficits in offspring of obese fathers and obese mothers were associated with a down-regulation of genes encoding NMDA glutamate receptors subunits and several learning-related genes along with impaired expression of miR-296 and miR-146b and increased concentration of kynurenic acid.
CONCLUSION: Paternal and maternal obesity impair offspring's learning abilities by affecting different processes of memory formation. These cognitive deficits are associated with epigenetic and neurochemical alterations leading to impaired glutamate-mediated synaptic plasticity.
The efficacy of REZLIDHIA was evaluated in an open-label, single-arm, multicenter clinical trial (Study 2102-HEM-101, NCT02719574) in 147 adult patients with relapsed or refractory AML with an IDH1 mutation.

IDH1 mutations in blood or bone marrow were confirmed retrospectively using the Abbott RealTime™ IDH1 Assay. REZLIDHIA was given orally at a dose of 150 mg twice daily until disease progression, development of unacceptable toxicity, or hematopoietic stem cell transplantation. Sixteen of the 147 patients (11%) underwent stem cell transplantation following REZLIDHIA treatment.

The baseline demographic and disease characteristics are shown in Table 4.

Efficacy was established on the basis of the rate of complete remission (CR) plus complete remission with partial hematologic recovery (CRh), the duration of CR+CRh, and the rate of conversion from transfusion dependence to transfusion independence. The efficacy results are shown in Table 5. The median follow-up was 10.2 months (range: 0.2 to 38.1 months) and median treatment duration was 4.7 months (range: 0.1 to 26.0 months).

Of the patients who achieved a CR or CRh, the median time to CR or CRh was 1.9 months (range: 0.9 to 5.6 months). All patients that achieved a best response of CR or CRh did so within 5.6 months of initiating REZLIDHIA.

Overall, among the 86 patients who were dependent on red blood cell (RBC) and/or platelet transfusions at baseline, 29 (34%) became independent of RBC and platelet transfusions during any 56-day post-baseline period. Of the 61 patients who were independent of both RBC and platelet transfusions at baseline, 39 (64%) remained transfusion independent during any 56-day post- baseline period.
NEW MATERIAL:The compound of formula I [R<1a> and R<2> are (substituted) 1-10C alkyl; R<3> is OH-protecting group or H; A is H and B is OH, or A and B together form a bond; X is H or halogen]. EXAMPLE:(4R)-5-[(1E)-6-methoxycarbonylhexylidene]-4-hydroxy-4- octyl-2-cyclo pentenone. USE:Pharmaceuticals. It has prostaglandin A-like structure, exhibits strong activity to inhibit the proliferation of cancer cells, and is expected to be useful as a carcinostatic agent. PREPARATION:The compound of formula I wherein A is H and B is OH can be prepared by carrying out the aldol condensation reaction of the 4-hydroxy-2- cyclopentenone compound of formula II with the aldehyde of formula III in a solvent in the presence of a basic compound, and if necessary, subjecting the product to the deprotection, hydrolysis, etc. Another compound of formula I wherein A and B together form a bond (the configuration of R<1> is E or Z) is obtained by the dehydration reaction of the above product.
Before the injection, the heart rate and blood pressure values of the patient were measured and recorded. The patient was placed in a prone position. The determined injection site was cleaned with a cotton pad with alcohol, with circular movements of 5 cm diameter from inside to outside, and the alcohol was allowed to dry. The protruding surface of the Shotblocker was placed in the area just before the injection, so that the needle entry point would not be contaminated. It was lightly pressed into the shotblocker with fingertips and the injection was performed. ShotBlocker has been removed after removing the needle. Visual comparison scale and injection satisfaction evaluation scale were applied to the patient in the first minute after the intramuscular injection. The obtained scores were recorded in the patient identification form. Pulse and blood pressure values were measured and recorded again. Finally, the patient introduction form was filled.
FOR TOPICAL OPHTHALMIC USE. NOT FOR INJECTION INTO THE EYE.

Sensitivity to topically applied aminoglycosides may occur in some patients. Severity of hypersensitivity reactions may vary from local effects to generalized reactions, such as erythema, itching, urticaria, skin rash, anaphylaxis, anaphylactoid reactions, or bullous reactions. If a sensitivity reaction does occur, discontinue use. 

Prolonged use of steroids may result in glaucoma, with damage to the optic nerve, defects in visual acuity and fields of vision, and posterior subcapsular cataract formation. Intraocular pressure (IOP) should be routinely monitored even though it may be difficult in pediatric patients and uncooperative patients. Prolonged use may suppress the host response and thus increase the hazard of secondary ocular infections. In acute purulent conditions and parasitic infections of the eye, steroids may mask infection or enhance existing infection.

In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical steroids.
Exemestane Exemestane type=equal unit=mg number=25 form=tablet route=oral use. All drugs are taken once daily.
Subject will be randomized to either test product/active comparator/placebo comparator. Active comparator is Ketaconazole 2% cream manufactured by Teva Pharmaceuticals USA.
This longitudinal prospective controlled multicenter study aimed to monitor immunity generated by three exposures caused by breakthrough infections (BTI) after COVID-19-vaccination considering pre-existing cell-mediated immunity to common-corona-viruses (CoV) which may impact cellular reactivity against SARS-CoV-2. Anti-SARS-CoV-2-spike-IgG antibodies (anti-S-IgG) and cellular reactivity against Spike-(S)- and nucleocapsid-(N)-proteins were determined in fully-vaccinated (F) individuals who either experienced BTI (F+BTI) or had booster vaccination (F+Booster) compared to partially vaccinated (P+BTI) and unvaccinated (U) from 1 to 24 weeks post PCR-confirmed infection. High avidity anti-S-IgG were found in F+BTI compared to U, the latter exhibiting increased long-lasting pro-inflammatory cytokines to S-stimulation. CoV was associated with higher cellular reactivity in U, whereas no association was seen in F. The study illustrates the induction of significant S-specific cellular responses in F+BTI building-up basic immunity by three exposures. Only U seem to benefit from pre-existing CoV immunity but demonstrated inflammatory immune responses compared to F+BTI who immunologically benefit from enhanced humoral and cellular immunity after BTI. This study demonstrates that individuals with hybrid immunity from COVID-19-vaccination and BTI acquire a stable humoral and cellular immune response that is maintained for at least 6 months. Our findings corroborate recommendations by health authorities to build on basic immunity by three S-protein exposures.
A material for sealing dentinal lumen by in-situ generation of calcium phytate and application thereof, belonging to the technical field of dental materials. Comprises an acid solution of calcium phytate as a reagent A. The reagent B is alkaline solution of calcium hydroxide, potassium hydroxide, sodium hydroxide, etc. The reagent A is coated on the surface of exposed dentin or placed in a root canal, the reagent A enters the inside of a dentin tubule, a lateral branch root canal and the like and can reach an apical pore along the root canal, and then the reagent B is coated, so that calcium phytate precipitate can be generated in an acidic solution of calcium phytate in the dentin tubule, the lateral branch root canal or the apical pore along with the increase of the pH value, and the dentin tubule, the lateral branch root canal or the apical pore is blocked. Hydrophilic components such as ethanol, ethylene glycol and acetone can be added into the reagent A or the reagent B to improve the permeability of the reagent A or the reagent B and further seal dentinal tubules, collateral roots and apical pores. Elements such as silicon-containing compounds and the like can also be added into the reagent B to assist in inducing calcium salt deposition in oral cavities and tissues, and further seal dentinal tubules, collateral roots and apical pores.
A triple natural polymer viscoelastic composition is disclosed. By combining glucosamine sulfate ("GS"), sodium hyaluronate ("HA") and chondroitin sulfate ("CS"), the triple natural polymer viscoelastic compositions of this invention can provide a viscoelastic agent at a surgical site that not only serves as a protective agent to ocular tissues, but that can also act as an agent to alleviate pain and inflammation associated with ocular surgery. Embodiments of this invention can comprise GS combined with existing HA/CS viscoelastic agents. Embodiments of this invention can also comprise GS and CS in combination with an irrigation solution. Further, to enhance retention time at the site of an intra-articulate application of an embodiment of this invention, the following biodegradable polymers may also be included in an embodiment of the compositions of the present invention: cellulose derivatives (e.g., hydroxypropylmethylcellulose, ethylcellulose, caboxymethylcellulose, etc.), carbopol , citosan, and collagen.
PURPOSE:The titled cosmetic having high safety, keeping a feeling of moisture till tomorrow morning and improved effect on skin, obtained by blending an N-long-chain acylmethyltaurine salt as an ionic surface active agent with a water-soluble polyhydric alcohol having a specific solubility parameter. CONSTITUTION:An oil-in-water type emulsion cosmetic comprising an emulsion composition containing an N-long-chain acylmethyltaurine salt (e.g. N- stearoylmethyltaurine acid sodium, etc.) as an ionic surface active agent (emulsifying agent), a component comprising one or a blend of water-soluble polyhydric alcohols (e.g. dipropylene glycol, 1,3-butylene glycol, etc.) having 12.5-18 solubility parameter or a combination of the water-soluble polyhydric alcohols and water and an oily phase component such as liquid paraffin, etc., and water. Use of a combination of the N-long-chain acylmethyltaurine salt and lecithin as the ionic surface active agent further improves stability.
FIELD: organic chemistry, medicine, pharmacy. SUBSTANCE: invention relates to derivative of thiophene of the formula (I)   where R a  and R b  can be similar or different and they mean hydrogen atom, alkyl, acyl, alkenyl, phenyl; or R a  and R b  in common can form benzene ring or cyclohexene ring, its pharmaceutically acceptable salts and hydrates. Compound of the formula (I) is useful as new antipsychotic agent exhibiting efficiency with respect both positive and negative symptoms in schizophrenia and gives less dangerous adverse effects. Except for, this compound is useful as medicinal agent for treatment of Alzheimer's disease and circular psychosis. EFFECT: valuable medicinal properties of compound. 18 cl
Cystic fibrosis transmembrane conductance regulator (CFTR) is a chloride (Cl-) channel regulated by phosphorylation and intracellular nucleotides. CFTR is the major Cl- transport pathway in airway epithelial cells. The abnormal transepithelial Cl- transport and subsequent defective fluid transport caused by CF is a result of the genetic mutations of the gene coding for the CFTR protein. The present invention is directed to the novel use of ionophores as artificial Cl- transport pathways into CF epithelia to treat the defective Cl- and fluid transport. Ionophores and in particular, small molecule ionophores, represent a potential novel means of treating CF. The invention also includes using an ionophore to generate chloride secretion on intact monolayers of airway epithelia cells and other epithelia cells by administering an ionophore to a mammal.
Participants in this condition will not receive the guided self-help intervention. They will receive treatment as usual and weekly feedback on their eating disorder symptoms for a period of 6 weeks.
Patients in reduction group 2 receive exactly 50% of their previous disease modifying therapy of conventional DMARD, biologicals and glucocorticoids during the first six months of the study. If they are still in remission they will discontinue their previous disease modifying therapy of conventional DMARD, biologicals and glucocorticoids during the first six months of the study.